Identification
Personal identification
- Full name
- Cristina Maria Godinho Pires João
Citation names
- Cristina João
Author identifiers
- Ciência ID
- F812-814B-AEED
- ORCID iD
- 0000-0002-3978-766X
Email addresses
- cristina.joao@fundacaochampalimaud.pt (Professional)
- cristina.joao@research.fchampalimaud.org (Professional)
- cristina.joao@research.fchampalimaud.org (Personal)
Addresses
- Fundação Champalimaud. Av Brasilia, 1044, Lisboa, Lisboa, Portugal (Professional)
Websites
- https://www.fchampalimaud.org/researchfc/groups/grupo-myeloma-lymphoma (Professional)
- https://www.fchampalimaud.org/centroclinicofc/unidades/hemato-oncologia (Professional)
Knowledge fields
- Medical and Health Sciences - Clinical Medicine - Hematology
- Medical and Health Sciences - Basic Medicine - Immunology
- Medical and Health Sciences - Clinical Medicine - Oncology
- Medical and Health Sciences - Clinical Medicine - Other Clinical Medicine Subjects
Languages
Language | Speaking | Reading | Writing | Listening | Peer-review |
---|---|---|---|---|---|
English | Advanced (C1) | Advanced (C1) | Advanced (C1) | Advanced (C1) | |
French | Beginner (A1) | Intermediate (B1) | Beginner (A1) | Beginner (A1) | |
Portuguese | Advanced (C1) | Advanced (C1) | Advanced (C1) | Advanced (C1) | |
Spanish; Castilian | Intermediate (B1) | Intermediate (B1) | Beginner (A1) | Intermediate (B1) |
Education
Degree | Classification | |
---|---|---|
2008/02/22 - 2018/08/14
Concluded
|
Consultant Degree in Clinical Hematology (Outros)
Major in Clinical Hematology
ACSS- Administração Central do Sistema de Saude, Portugal
|
17/20 |
2008/03/04
Concluded
|
Master's in Biomedical Sciences, Clinical Investigation (Mestrado integrado)
Major in Master's in Biomedical Sciences, Clinical Investigation
Universidade Nova de Lisboa, Portugal
"B cell dependent T cell development" (THESIS/DISSERTATION)
|
Approved |
1998/01/02 - 2008/02/22
Concluded
|
Clinical Hematology Specialist (Título de especialista)
Major in Clinical Hematology
Ordem dos Médicos, Portugal
|
19,9/20 |
2008
Concluded
|
Medicine (Doutoramento)
Major in Specialty: Internal Medicine
Universidade NOVA de Lisboa NOVA Medical School, Portugal
"Reconstituição do Reportório Imunológico em Contexto de Transplantação Hematopoiética / Reconstitution of the Immunological
Repertoire in the Context of Hematopoietic Transplantation" (THESIS/DISSERTATION)
|
|
2004 - 2006
Concluded
|
Master in Clinical Research (Master)
Major in Investigação Clinica
Mayo Clinic Cancer Center, United States
"B cell dependent T cell development" (THESIS/DISSERTATION)
|
Excelent |
1997 - 1997
Concluded
|
Ensino prático - como fazer, como avaliar? / Practical teaching - how to do it, how to evaluate it? (Especialização pós-licenciatura)
Major in Medical Education
Universidade de Lisboa Faculdade de Medicina, Portugal
|
Apta |
1997 - 1997
Concluded
|
Advances in Immunology (Especialização pós-licenciatura)
Major in Imunologia
Instituto Gulbenkian de Ciência, Portugal
|
Apta |
1996/07 - 1996/08
Concluded
|
The 1st Copenhagen International Interdisciplinary School in Biological Science: "The spontaneous order of life - in search
of the loss of self-organization in Physical, Biological and Cognitive Systems" (Postgraduate Certificate)
Major in Biological Systems
Københavns Universitet Niels Bohr Instituttet, Denmark
|
Pass |
1990/09 - 1996/07/22
Concluded
|
Medicine (Licenciatura)
Universidade de Lisboa Faculdade de Medicina, Portugal
|
18/20 |
Affiliation
Teaching in Higher Education
Category Host institution |
Employer | |
---|---|---|
2010/02/01 - Current | Invited Assistant Professor (University Teacher) | Universidade Nova de Lisboa Faculdade de Ciências Médicas, Portugal |
Universidade Nova de Lisboa Faculdade de Ciências Médicas, Portugal | ||
2016/09/01 - 2021/07/31 | Lecturer (University Teacher) | Centro Hospitalar e Universitario de Coimbra EPE Campus dos Hospitais da Universidade de Coimbra, Portugal |
Centro Hospitalar e Universitario de Coimbra EPE Campus dos Hospitais da Universidade de Coimbra, Portugal | ||
2019/10/14 - 2019/10/16 | Lecturer (University Teacher) | Sociedade Portuguesa de Hematologia, Portugal |
Sociedade Portuguesa de Hematologia, Portugal | ||
2016 - 2016 | Visiting Professor (University Teacher) | Janssen Pharmaceuticals Inc, Hungary |
Janssen Pharmaceuticals Inc, Hungary | ||
2011/09/01 - 2012/06/30 | Invited Assistant (University Teacher) | Université Sorbonne Paris Nord UFR de Santé Médecine Biologie Humaine, France |
Université Sorbonne Paris Nord UFR de Santé Médecine Biologie Humaine, France | ||
2007/10/01 - 2008/03/31 | Invited Associate Professor (University Teacher) | Universidade de Lisboa Instituto de Medicina Preventiva e Saúde Pública, Portugal |
Universidade de Lisboa Instituto de Medicina Preventiva e Saúde Pública, Portugal (...) |
Positions / Appointments
Category Host institution |
Employer | |
---|---|---|
2023/11/01 - Current | Directors Board member of EuroFlow | EuroFlow, Netherlands |
2023/11/01 - Current | Assembly secretary | Sociedade Portuguesa de Hematologia, Portugal |
2021/12/01 - Current | Directors Board member of the Multiple Myeloma Group | Sociedade Portuguesa de Hematologia, Portugal |
2019 - Current | Research Group Leader | Fundação Champalimaud, Portugal |
2018/08/14 - Current | Hematologist Consultant | Fundação Champalimaud, Portugal |
2015/01/01 - Current | Member of the Bone and Imaging Working Committee | International Myeloma Foundation, United States |
International Myeloma Working Group, United States | ||
2015/01/01 - Current | Member of the Smouldering Multiple Myeloma Working Committee | International Myeloma Foundation, United States |
International Myeloma Working Group, United States |
Others
Category Host institution |
Employer | |
---|---|---|
2008/04/01 - 2015/05/01 | Hematology Assistant (clinical responsabilities at the Hematology Department, IPO Lisboa) | Instituto Português de Oncologia de Lisboa Francisco Gentil EPE, Portugal |
Instituto Português de Oncologia de Lisboa Francisco Gentil EPE, Portugal | ||
2008/01/01 - 2015/05/01 | Researcher (Principal Investigator, Scientific Research on Immune Reconstitution) | Instituto Português de Oncologia de Lisboa Francisco Gentil EPE Unidade de Investigação em Patobiologia Molecular, Portugal |
Instituto Português de Oncologia de Lisboa Francisco Gentil EPE Unidade de Investigação em Patobiologia Molecular, Portugal | ||
2009 - 2014 | Principal Investigator | Universidade Nova de Lisboa Centro de Estudos de Doenças Crónicas, Portugal |
2006/06/01 - 2010/01/01 | External Research Collaborator | Mayo Clinic Cancer Center, United States |
1999/01/01 - 2008/03/01 | Resident in Clinical Hematology (interrupted to PhD studies between 2003 and 2006) | Instituto Português de Oncologia de Lisboa Francisco Gentil EPE, Portugal |
2006 - 2008 | Research Collaborator | Instituto Gulbenkian de Ciência, Portugal |
2005 - 2006 | External Post doctoral Research Fellow | Mayo Clinic Cancer Center, United States |
2002/06 - 2005 | Post doctoral Research Fellow | Mayo Clinic Cancer Center, United States |
1997/01/01 - 1998/12/31 | General Residency | Hospital Distrital De Santarém Epe, Portugal |
1995/09/01 - 1997/07/01 | Hired assistant of Histology and Embriology | Universidade de Lisboa Faculdade de Medicina, Portugal |
Projects
Grant
Designation | Funders | |
---|---|---|
2022/10/02 - 2024/06/30 | Study of the neuronal role on the interplay between NK cells and Multiple Myeloma (NeuriMM)
Study of the neuronal role on the interplay between NK cells and Multiple Myeloma (NeuriMM)
Principal investigator
Fundação Champalimaud, Portugal
|
Associação Portuguesa Contra a Leucemia Sociedade Portuguesa de Hematologia Amgen - Bio - Farmacêutica, Lda Ongoing
|
2009/01 - 2012/06 | Lupus and its compensation in unaffected relatives by T-cell regulation
Researcher
|
Fundação para a Ciência e a Tecnologia
Concluded
|
2010 - 2011 | Assessment of T cell receptor diversity in different imbalance immunological conditions using CDR3 spectratyping
FCT_ProgramaPessoa2010
Principal investigator
Instituto Português de Oncologia de Lisboa Francisco Gentil EPE Unidade de Investigação em Patobiologia Molecular, Portugal
Instituto Gulbenkian de Ciência, Portugal Sorbonne Université Faculté de Médecine Campus Pitié-Salpêtrière, France |
Fundação para a Ciência e a Tecnologia
Concluded
|
2007 - 2011 | B cell modulation of T cells function and repertoire - immune characterization of lymphoma patients receiving chemotherapy
with or without a B cell depleting agent, Rituximab
APCL2007
Principal investigator
Instituto Português de Oncologia de Lisboa Francisco Gentil EPE Unidade de Investigação em Patobiologia Molecular, Portugal
|
Associação Portuguesa contra a Leucemia
Concluded
|
2007/09 - 2010/12 | Quantitative and Qualitative T cell receptor repertoire requirements for immune tolerance establishment and maintenance
Researcher
|
Fundação para a Ciência e a Tecnologia |
2002/07/01 - 2006/05/31 | B cell-dependent T cell development and function
SFRH/BD/6797/2001
Universidade NOVA de Lisboa NOVA Medical School, Portugal
|
Fundação para a Ciência e a Tecnologia
Concluded
|
2002 - 2006 | Immune reconstitution after bone marrow transplantation
SFRH/BD/6797/2001
PhD Student Fellow
Fundação para a Ciência e a Tecnologia, Portugal
|
Fundação para a Ciência e a Tecnologia
Concluded
|
2001 - 2002 | Cytogenetic abnormalities in MALT lymphomas
GHOP_MALT Lymphomas2001
Principal investigator
Instituto Português de Oncologia de Lisboa Francisco Gentil EPE, Portugal
|
GHOP – Portuguese Group of Onco-Hematology Fellowship
Concluded
|
Contract
Designation | Funders | |
---|---|---|
2020/11/25 - Current | Exploring the bone marrow microenvironment communication via extracellular vesicles in an immunocompetent multiple myeloma
mouse models and its potential translation to human disease
Refª - PGG/058/2019
Refª - PGG/058/2019
Principal investigator
Fundação Champalimaud, Portugal
|
Gilead Sciences Lda
Concluded
|
2019/07 - Current | LyRaCAD (Sistema CAD para análise de imagens PET/CT com 18F-FDG em linfomas – uma abordagem radiomics)
POCI-01-0247-FEDER-039885
Researcher
Fundação Champalimaud, Portugal
|
Horizon 2020
Ongoing
|
2019 - Current | Zebrafish avatar for CLL therapy screening
Kickstarters 2019
Fundação Champalimaud, Portugal
|
Fundação Champalimaud
Ongoing
|
2017 - Current | The role of metastatic microenvironment in Multiple Myeloma extramedullary disease (EMphAsIS)
PTDC/MEC-HEM/30315/2017
Fundação Champalimaud, Portugal
|
Ongoing
|
2015 - Current | Phase 3 Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide
(CC-5013) Plus R-CHOP Chemotherapy (R2-CHOP) Versus Placebo Plus R-CHOP Chemotherapy in Subjects with Previously Untreated
Activated B-cell Type Diffuse Large B-cell Lymphoma
CC-5013-DLC-002
CC-5013-DLC-002
Researcher
Instituto Português de Oncologia de Lisboa Francisco Gentil EPE, Portugal
|
Celgene Portugal
Ongoing
|
2023/11/01 - 2025/10/31 | Identification of non-invasive genetic biomarkers predicting Daratumumab plus carfilzomib and dexamethasone response in Multiple
Myeloma
IIS RESEARCH SUPPORT APPLICATION INVESTIGATOR-INITIATED STUDY
Co-Principal Investigator (Co-PI)
Fundação Champalimaud, Portugal
|
Janssen Global Services LLC
Ongoing
|
2022/01/01 - 2024/12/31 | Unic.MM: Combined immunotherapy as a strategy for manipulating the bone marrow microenvironment in multiple myeloma
PTDC/MED-ONC/1215/2021
Principal investigator
Fundação Champalimaud, Portugal
Universidade Nova de Lisboa, Portugal Universidade Nova de Lisboa Centro de Toxicogenómica e Saúde Humana, Portugal Universidade de Lisboa Instituto de Medicina Molecular João Lobo Antunes, Portugal |
Fundação para a Ciência e a Tecnologia
Ongoing
|
2016/11/04 - 2023/03/10 | TOURMALINE - A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide
and Dexamethasone in Adult Participants With Relapsed and/¿or Refractory Multiple Myeloma
Principal investigator
Fundação Champalimaud, Portugal
Takeda Global Research and Development Center Inc, United States |
Takeda Global Research and Development Center Inc
Concluded
|
2018/12/03 - 2022/07/01 | EMphAsIS_The role of metastatic microenvironment in Multiple Myeloma extramedullary disease.
FCT-PTDC/MEC-HEM/30315/2017
PTDC/MEC-HEM/30315/2017
PTDC/MEC-HEM/30315/2017
Principal investigator
Fundação Champalimaud, Portugal
|
Fundação para a Ciência e a Tecnologia N/A Ongoing
|
2021/01/28 - 2021/03/10 | Study of the neuronal role on the interplay between NK cells and Multiple Myeloma (NeuriMM)
2022.08762.PTDC
Researcher
Fundação Champalimaud, Portugal
|
Fundação para a Ciência e a Tecnologia
Ongoing
|
2016 - 2018 | Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed
Multiple Myeloma Not Treated With Stem Cell Transplantation
Principal investigator
Fundação Champalimaud, Portugal
|
Takeda Farmacêuticos Portugal
Concluded
|
2013 - 2015 | Open-label study with Pomalidomide in Combination with Low Dose Dexamethasone in subjects with Refractory or Relapsed and
Refractory Multiple Myeloma
CC-4047-MM-010
Principal investigator
Celgene Portugal, Portugal
|
Celgene Portugal
Concluded
|
2013 - 2015 | A Randomized, Controlled, Open-Label, Multicenter Phase 3 Study of the Bruton’s Tyrosine Kinase (Btk) Inhibitor, Ibrutinib,
versus Temsirolimus in Subjects with Relapsed or Refractory Mantle Cell Lymphoma Who Have Received At least One Prior Therapy
NCT01646021
Principal investigator
Instituto Português de Oncologia de Lisboa Francisco Gentil EPE, Portugal
|
Janssen-Cilag Farmacêutica Lda
Concluded
|
2011/03/15 - 2014/09/14 | Chronic intermittent eucapnic hypoxia: systemic effects and assessment of the efficacy of antihypertensive drugs
PTDC/SAU-TOX/112264/2009
Universidade NOVA de Lisboa NOVA Medical School, Portugal
Universidade Nova de Lisboa Centro de Estudos de Doenças Crónicas, Portugal Universidad de Valladolid, Spain Instituto de Biologia Experimental e Tecnológica, Portugal Instituto Português de Oncologia de Lisboa Francisco Gentil EPE, Portugal |
Fundação para a Ciência e a Tecnologia
Concluded
|
2010 - 2014 | Randomized phase IIIb clinical trial of Mabthera (Rituximab) added to chemotherapy, Bendamustine or Chlorambucil, in patients
with Chronic Lymphocytic Leukemia
MO22468
Principal investigator
Instituto Português de Oncologia de Lisboa Francisco Gentil EPE, Portugal
|
Roche Farmaceutica Quimica Lda
Concluded
|
2010 - 2013 | Chronic Intermittent Eucapnic Hypoxia: systemic effects and evaluation of anti-hypertensive drugs efficacy
PTDC/SAL-TOX/112264/2009
Researcher
Fundação para a Ciência e a Tecnologia, Portugal
Universidade Nova de Lisboa Centro de Estudos de Doenças Crónicas, Portugal |
Fundação para a Ciência e a Tecnologia
Concluded
|
2009/01/01 - 2012/06/30 | Lupus and its compensation in unaffected relatives by T cell regulation
PIC/IC/82746/2007
Fundação Calouste Gulbenkian, Portugal
Instituto Gulbenkian de Ciência, Portugal Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal Associacao de Doentes com Lupus, Portugal Hospital Geral de Santo António SA, Portugal Universidade de Trás-os-Montes e Alto Douro Centro de Investigação e de Tecnologias Agro-Ambientais e Biologicas, Portugal |
Fundação para a Ciência e a Tecnologia
Concluded
|
2007/09/01 - 2010/12/31 | Repertoire of T cell receptors in the generation and maintenance of immunological tolerance: Qualitative and quantitative
requirements.
PTDC/SAU-MII/71402/2006
Researcher
Fundação Calouste Gulbenkian, Portugal
Instituto Gulbenkian de Ciência, Portugal Universidade de Trás-os-Montes e Alto Douro Centro de Investigação e de Tecnologias Agro-Ambientais e Biologicas, Portugal |
Fundação para a Ciência e a Tecnologia
Concluded
|
2007/09/01 - 2010/08/31 | Immune reconstitution after Autologous Hematopoietic Stem Cell Transplantation - modulation by immunoglobulins and potential
clinical application
PTDC/SAU-MII/65029/2006
Principal investigator
Fundação Calouste Gulbenkian, Portugal
Instituto Gulbenkian de Ciência, Portugal Instituto Português de Oncologia de Lisboa Francisco Gentil EPE, Portugal Universidade de Trás-os-Montes e Alto Douro Centro de Investigação e de Tecnologias Agro-Ambientais e Biologicas, Portugal Institut Pasteur, France |
Fundação para a Ciência e a Tecnologia
Concluded
|
2007 - 2010 | Lupus and its compensation in unaffected relatives by T-cell regulation
PIC/IC/82746/2007
Researcher
Fundação para a Ciência e a Tecnologia, Portugal
|
Fundação para a Ciência e a Tecnologia
Concluded
|
2007/09/01 - 2009 | Immune recovery after Autologous Stem Cell Transplantation - modulation by Ig and potential clinical application
2006-30.4M.AP/MJ
PTDC/SAU-MII/65029/2006
Principal investigator
Associação Portuguesa contra a Leucemia, Portugal
Fundação para a Ciência e a Tecnologia, Portugal |
Associação Portuguesa contra a Leucemia Fundação para a Ciência e a Tecnologia Concluded
|
Other
Designation | Funders | |
---|---|---|
2023/01/23 - Current | VOLTA project
Technical development
|
|
2023/01/01 - Current | CarMMa - Characterization of the Population of Patients with Multiple Myeloma Treated in Portuguese Hospitals and Characterization
of Their Caregivers
CarMMa
Principal investigator
|
Ongoing
|
2023/06/02 - 2033/11/30 | SUCCESSOR-1 - A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone
(PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Principal investigator
Fundação Champalimaud, Portugal
Celgene, United States |
Celgene
Ongoing
|
2022/10/17 - 2032/06/25 | EXCALIBER-RRMM - Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib,
and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Principal investigator
Celgene, United States
Fundação Champalimaud, Portugal |
Celgene
Ongoing
|
2023/07/28 - 2031/08/31 | MajesTEC-9 - A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib,
Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
Principal investigator
Janssen Research & Development, LLC, United States
Fundação Champalimaud, Portugal |
Janssen Research & Development, LLC
Ongoing
|
2023/03/03 - 2027/04/06 | MK-2140-006 - A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive
and Indolent B-cell Malignancies
Principal investigator
Fundação Champalimaud, Portugal
Merck Sharp & Dohme Corp, United States |
Merck Sharp & Dohme Corp |
2021/12/03 - 2027/02/05 | ESCALADE - A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
Principal investigator
AstraZeneca Pharmaceuticals LP, United States
Fundação Champalimaud, Portugal |
AstraZeneca Pharmaceuticals LP
Ongoing
|
2021/11/12 - 2026/11/01 | CONPET - Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment.
Principal investigator
Oslo universitetssykehus, Norway
Fundação Champalimaud, Portugal |
Oslo universitetssykehus |
2023/04/14 - 2026/04/27 | IMPACTMF - A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis
(MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
Principal investigator
Geron Corporation, United States
Fundação Champalimaud, Portugal |
Geron Corporation
Ongoing
|
2021/10/26 - 2025/04/01 | LOXO-BRUIN - Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
(BRUIN-MCL-321)
Principal investigator
Loxo Oncology Inc, United States
Fundação Champalimaud, Portugal |
Loxo Oncology Inc
Ongoing
|
2023/10/17 - 2024/07/17 | ACT17453 - A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants
With Relapsed and/or Refractory Multiple Myeloma
Principal investigator
Fundação Champalimaud, Portugal
Sanofi SA Research and Development Waltham, United States |
Sanofi SA Research and Development Waltham
Ongoing
|
2021/08/17 - 2023/12/29 | CAS-OFLYRICLB - Evaluation of the Chronic Lymphoproliferative Diseases Limited Panel on the BD FACSLyric™ Flow Cytometer
Researcher
Fundação Champalimaud, Portugal
Becton, Dickinson and Company, United States |
Becton, Dickinson and Company
Cancelled
|
2022/07/29 - 2023/11/07 | KRT232-101_BOREAS - KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed
or Refractory to JAK Inhibitor Treatment
Principal investigator
Kartos Therapeutics, Inc., United States
Fundação Champalimaud, Portugal |
Kartos Therapeutics, Inc.
Concluded
|
2021/10/22 - 2023/10/25 | CAS-OFLYRICPP - Evaluation of the Plasma Cell Disorders Panel on the BD FACSLyric™ Flow Cytometer
Researcher
Becton, Dickinson and Company, United States
Fundação Champalimaud, Portugal |
Becton, Dickinson and Company
Concluded
|
2015/11/16 - 2023/10/04 | ALCYONE - A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone
(VMP) in Participants With Previously Untreated Multiple Myeloma
Principal investigator
Fundação Champalimaud, Portugal
Janssen Research and Development Belgium Discovery Process Research Group, Belgium |
Janssen Research and Development Belgium Discovery Process Research Group
Ongoing
|
2022/12/06 - 2023/09/01 | CAS-OFLBT1T4 - BD OneFlow CLPD Panel (BD OneFlow LST and B-CLPD assays T1 to T4) in the BD FACSLyric System.
Researcher
Fundação Champalimaud, Portugal
Becton Dickinson and Company, United States |
Becton Dickinson and Company
Ongoing
|
2022/07/29 - 2023/06/30 | KRT232-111 - Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
Principal investigator
Fundação Champalimaud, Portugal
Kartos Therapeutics, Inc., United States |
Kartos Therapeutics, Inc.
Concluded
|
2021/03/09 - 2023/04/28 | MRDeep - Prevalence of minimal residual disease (MRD) in patients treated for Multiple Myeloma (MM) who reach complete response
and are currently on 2nd or 3rd line of therapy for MM
MRDEEP
Principal investigator
Janssen Global Services LLC, United States
Fundação Champalimaud, Portugal |
Janssen Global Services LLC |
2020/05/04 - 2023/04/17 | FIRST-MIND - Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition
to R-CHOP in Patients With Newly Diagnosed DLBCL
Principal investigator
Fundação Champalimaud, Portugal
MorphoSys AG, Germany |
MorphoSys AG
Concluded
|
2021/09/10 - 2023/01/30 | ENHANCE - Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL
Principal investigator
Cornell University Joan and Sanford I Weill Medical College, United States
Fundação Champalimaud, Portugal |
Cornell University Joan and Sanford I Weill Medical College
Concluded
|
2019/08/02 - 2022/12/19 | EMN23/54767414AMY0001 - A Retrospective Observational Multicenter Study on the Management and Outcome of Patients With Systemic
AL Amyloidosis in Europe
Principal investigator
European Myeloma Network, Netherlands
Fundação Champalimaud, Portugal |
European Myeloma Network
Concluded
|
2017/09/01 - 2018/08/31 | Atlas-based semi-automatic segmentation of Whole-Body DWI Images: Quantification of tumour burden
Kickstarter
Principal investigator
Fundação Champalimaud, Portugal
|
Fundação Champalimaud
Concluded
|
Outputs
Publications
Book chapter |
|
Conference abstract |
|
Conference paper |
|
Conference poster |
|
Journal article |
|
Newspaper article |
|
Other
Other output |
|
Activities
Oral presentation
Presentation title | Event name Host (Event location) |
|
---|---|---|
2023/05/13 | Multiple Myeloma and adjacent NK cells can express the machinery to integrate neuronal signals | 31st Sabbath in Hematology
Centro Hospitalar da Universidade de Coimbra (Coimbra, Portugal)
|
2021/12/11 | Systemic light chain amyloidosis across Europe: Key outcomes from a retrospective study of 4500 patients | The American Society of Hematology Annual Meeting & Exposition, Atlanta, USA
American Society of Hematology (Atlanta, United States)
|
2020/10/12 | First glimpse on real-world efficacy outcomes for 2000 patients with systemic light chain amyloidosis in Europe: a retrospective observational multicenter study by the european myeloma network. | American Society of Hematology meeting
(United States)
|
2020/02/12 | Statistical methods for the study of extracellular vesicles content and their potencial as biomarkers of multiple myeloma aggressiveness | iMed Conference
Universidade Nova de Lisboa Faculdade de Ciências Médicas (Lisboa, Portugal)
|
2016/11 | Treatment of Multiple Myeloma old patients - a Portuguese multicentric real-life study | Annual Meeting of the Portuguese Society of Hematology
Portuguese Society of Hematology (Povoa do Varzim, Portugal)
|
2014 | New therapies in Hemato-oncology Immunotherapy and intra cellular signaling inhibition | Annual Meeting of the Portuguese Society of Human Genetics
Portuguese Society of Human Genetics
|
2012/11/10 | Lenalidomide in the treatment of relapsed/refractory Multiple Myeloma - Importance of early treatment on overall survival | Annual meeting of Sociedade Portuguesa de Hematologia
Sociedade Portuguesa de Hematologia (Porto, Portugal)
|
2012/10/10 | Respiratory amyloidosis, from surprise to panic | XXVIII Pulmonology Congress
Sociedade Portuguesa de Pneumologia (Tróia, Portugal)
|
2012/01/26 | Monoclonal gammopathies - From biology to treatment | Atualizações em Oncologia 2012, 26ª Reunião - 1º Congresso do Cimago
Linha de Investigação Clínica e Interdisciplinar em Meio Ambiente, Genética e Oncobiologia (Coimbra, Portugal)
|
2011/11/11 | Treatment with low-dose polyclonal immunoglobulin improves B lymphocyte cell function during immune reconstitution. | Anual Meeting of Sociedade Portuguesa de Hematologia
Sociedade Portuguesa de Hematologia (Albufeira, Portugal)
|
2010/11/12 | MPT as first-line treatment in multiple myeloma patients not eligible for transplant: a Portuguese multicenter study | Anual meeting of Sociedade Portuguesa de Hematologia
Sociedade Portuguesa de Hematologia (Tróia, Portugal)
|
2009 | A decade of thalidomide use in multiple myeloma patients - Experience from the Hematology Department of IPOFG, Lisbon | Jornadas do ROR Sul
Registo Oncológico Regional (Lisboa, Portugal)
|
2009 | Immunological interdependencies between B and T lymphocytes | “Manuela Correia lecture”, Annual Meeting of Sociedade Portuguesa de Hematologia
Sociedade Portuguesa de Hematologia (Tróia, Portugal)
|
2008/11/14 | Treatment with immunoglobulin or molecule fragments after hematopoietic precursor transplantation increases peripheral cell proliferation | Anual Meeting of Sociedade Portuguesa de Hematologia
Sociedade Portuguesa de Hematologia (Torres Vedras, Portugal)
|
2007/11/10 | Effect of immunoglobulin or its derivatives infusion on immune reconstitution after autologous hematopoietic stem cell transplantation (ASCT) in an animal model (mouse) | Anual Meeting of Sociedade Portuguesa de Hematologia
Sociedade Portuguesa de Hematologia (Albufeira, Portugal)
|
2007 | Treatment with polyclonal immunoglobulin and its fragments optimize recovery of IgM serum levels after autologous stem cells transplantation (ASCT) | Reunião Anual da Sociedade Portuguesa de Imunologia
Sociedade Portuguesa de Imunologia (Lisboa, Portugal)
|
2007 | Immune reconstitution after autologous stem cell transplantation | Scientific meeting
Unidade de Investigação em Patobiologia Molecular, Francisco Gentil’s - Portuguese Oncology Institute (Lisboa, Portugal)
|
2005/04 | Immunoglobulin Heavy Chain and the life of Memory B cells - Abstract 47.2 | FASEB Research Conference - American Society of Immunology Meeting
Federation of American Societies for Experimental Biology (san Diego, United States)
|
2005 | Survival of B Cells Lacking Surface Ig | Keystone B cells Meeting
(Colorado, United States)
|
2004/12 | Driving T cell development in the thymus, abstract # 3860 | American Society of Hematology meeting, 2004, San Diego, USA.
American Society of Hematology (San Diego, United States)
|
2004/11 | Impact of B lymphocytes on T lymphocyte development | Annual Meeting of Sociedade Portuguesa de Hematologia
Sociedade Portuguesa de Hematologia (Portugal)
|
2004/06 | A new road to T cell diversification | 9th Congress of the European Hematology Association
European Hematology Association (Genebra, Switzerland)
|
2004/05 | T cell repertoire expansion by B cells and immunoglobulin | American Transplantation Congress Annual Meeting
American Transplantation Congress (Boston, United States)
|
2004/04 | B cells directed-T cell development | American Society of Immunology Meeting, FASEB 2004
FASEB (Washington, D.C., United States)
|
2004 | Heavy chain promotes positive selection of CD4 T cells | Annual Meeting of the Portuguese Society of Immunology
Portuguese Society of Immunology (Lisbon, Portugal)
|
2004 | TCR diversity and immune responses to transplantation | Transplant Grand Rounds
Mayo Clinic (Rochester, United States)
|
2003/05 | Delayed rejection of male to female skin grafts by memory like T cells | American Transplantation Congress, 2003, Washington, D.C., USA.
American Transplantation Congress, (Washington, D.C., United States)
|
2002 | NK cell non’Hodgkin Lymphoma: A clinico-pathology entity of the Middle line Lethal Granuloma – clinical case | XV National Meeting of ENT and Cervico-Facial Surgery
National Society of ENT and Cervico-Facial Surgery (Aveiro, Portugal)
|
2001 | Anemia and Dyserythropoiesis - CDA II | XIV Sabatin of Hematology, Coimbra Hospital Center, 2001
Centro Hospitalar e Universitário de Coimbra (Coimbra, Portugal)
|
2000 | A case of Adult’s Still Disease | Intensive Care Portuguese Society Annual Simposum/First Santarém’s Congress of Intensive Care
Intensive Care Portuguese Society (Santarém, Portugal)
|
2000 | Paget’s Bone Disease associated with Myelofibrosis with Myeloid Metaplasia | 6th National Congress of Internal Medicine
National Congress of Internal Medicine (Porto, Portugal)
|
1999/11 | Review of 6 cases of Kikushi-Fugimoto Disease | Annual Meeting of the Portuguese Society of Hematology
Portuguese Society of Hematology (Estoril, Portugal)
|
Supervision
Thesis Title Role |
Degree Subject (Type) Institution / Organization |
|
---|---|---|
2020/11/09 - Current | Integration of neuronal signals by tumour-infiltrating natural killer and myeloma cells - NeuriMM
Supervisor of Ana Filipa Barahona Afonso Tavares Cardoso
|
PhD in Biomedicine (PhD)
Universidade Nova de Lisboa Faculdade de Ciências Médicas, Portugal
|
2020/09/14 - Current | Combined GEnetic and immuNe signatures associated with depth of response and Outcome in MultiplE Myeloma.
Supervisor of Joana Filipa de Jesus Caetano
|
PhD in Health Sciences (PhD)
Universidade Nova de Lisboa Faculdade de Ciências Médicas, Portugal
|
2021/01/01 - 2025/12/31 | Combined immunotherapeutic approach for targeting bone marrow microenvironment in Multiple Myeloma.
Supervisor of Ana Raquel Vicente Lopes
|
Programa Doutoral do Centro Académico de Medicina de Lisboa (ramo de Medicina; ramo de Ciências Biomédicas; ramo de Ciências
e Tecnologias da Saúde) (PhD)
Universidade de Lisboa Faculdade de Medicina, Portugal
|
2019/09/01 - 2021/03/31 | Statistical methods for the study of extracellular vesicles content and their potential as biomarkers of multiple myeloma
aggressiveness.
Co-supervisor of Carolina Festas Pestana
|
Bioestatística (Master)
Universidade de Lisboa Faculdade de Ciências, Portugal
|
2020/01/13 - 2020/02/21 | Internship integrated in the Discipline of Introductory Program to Professional Practice
Co-supervisor
|
Ciências de Engenharia Biomédica (Scientific initiation)
Universidade Nova de Lisboa Faculdade de Ciências e Tecnologia, Portugal
|
2019/03/01 - 2019/06/30 | Research Project Discipline integrated in curriculum of the Bachelor in Medicine.
Supervisor of Madalena Teixeira Santos de Sousa Gonçalves,
|
Medicina (Scientific initiation)
Universidade Nova de Lisboa Faculdade de Ciências Médicas, Portugal
|
2016 - 2019 | Thymic function and regulatory T cells in the immune recovery of HIV infected patients. Funding FCT: PD/BD/106047/2015
Co-supervisor of Rita Ribeiro da Silva
|
Medicina (PhD)
Universidade do Minho, Portugal
|
2017 - 2018 | Atlas-based semi-automatic segmentation of
Whole-Body DWI Images: Quantification of
tumour burden
Co-supervisor of Silvia Alexandra Dias Almeida
|
Ciências de Engenharia Biomédica (Master)
Universidade Nova de Lisboa Faculdade de Ciências e Tecnologia, Portugal
|
2017 - 2017 | The role of metastatic microenvironment in Multiple Myeloma extramedullary disease. Funding FCT: PTDC/MEC-HEM/30315/2017
Supervisor of Bruna Velosa Ferreira
|
Medicina (PhD)
Universidade Nova de Lisboa Faculdade de Ciências Médicas, Portugal
|
2017 - 2017 | B cells modulation of T cells' function and repertoire: immune characterization of Non Hodgkin Lymphoma patients receiving
chemotherapy, with or without the CD20 monoclonal antibody, Rituximab. Funding Associação Portuguesa Contra a Leucemia: APCL
2006-30.4M.AP/MJ
Supervisor
|
Bioquímica (Master)
Universidade de Évora Escola de Ciências e Tecnologia, Portugal
|
Event organisation
Event name Type of event (Role) |
Institution / Organization | |
---|---|---|
2023/03/18 - Current | Member of the scientific and organizing committee of the "First National Meeting on Multiple Myeloma". (2023/03/18)
Seminar (Member of the Scientific Committee)
|
Sociedade Portuguesa de Hematologia, Portugal |
2021/09/01 - Current | Champalimaud Foundation Scientific Research Colloquium (2023/09/01)
Seminar (Co-organisor)
|
Fundação Champalimaud, Portugal |
2021/03/24 - 2021/03/24 | Workshop: Sex and Gender Dimension in Your Research (2021/03/24 - 2021/03/24)
Round table (Co-organisor)
|
Fundação Champalimaud, Portugal |
Event participation
Activity description Type of event |
Event name Institution / Organization |
|
---|---|---|
2023/03/18 - Current | Speaker at the First National Meeting on Multiple Myeloma about "1st line treatment in multiple myeloma"
Meeting
|
First National Meeting on Multiple Myeloma
Sociedade Portuguesa de Hematologia, Portugal
|
2016/11/11 - Current | Invited speaker at the round table on "Immunotherapy": Lecture entitled "Immune mechanisms and intervention possibilities",
Lisbon, Portugal
Meeting
|
3º ABC em Imunologia para Médicos, Fundação Calouste Gulbenkian
Hospital CUF Descobertas, Portugal
|
2016/10/08 - Current | Invited speaker in "Focusing on Remission in Multiple Myeloma" (Celgene Satellite Symposium), Milan, Italy
Conference
|
3rd International Conference on Multiple Myeloma
European School of Hematology, France
|
2016/02/12 - Current | Invited speaker on "New imaging strategies for diagnosis and staging on Multiple Myeloma and Lymphoma", Lisbon, Portugal
Symposium
|
first ESOR/Champalimaud Foundation Symposium on “Imaging Hallmarks of Cancer”
Fundação Champalimaud, Portugal
|
2015 - Current | Invited speaker in Immunology meeting entitled "Mecanismos Imunes e possibilidades de intervenção", Oeiras, Portugal
Round table
|
ABC em Imunologia - Imunoterapia
Instituto Gulbenkian de Ciência, Portugal
|
2015 - Current | Invited speaker in "Novas abordagens da LLC- ibrutinib" |
CUF Infante Santo Hospital, Portugal
|
2022/11/10 - 2022/11/12 | Speaker on "Emotional adjustment of the person with hemato-oncologic disease" at the round table entitled "Multidimensionality:
Caring for the person with hemato-oncologic disease".
Round table
|
Annual Meeting 2022
Sociedade Portuguesa de Hematologia, Portugal
|
2022/11/10 - 2022/11/12 | Speaker at the Satellite Symposium on "BLENREP - Innovation in MM treatment: From studies to clinical practice".
Symposium
|
Anual meeting 2022
Sociedade Portuguesa de Hematologia, Portugal
|
2021/10/06 - 2021/11/30 | Invited Speaker at the Online Course Actualización en onconefrología organized by "La Sociedad Latinoamericana de Nefrología
e Hipertensión (SLANH)" with the educational, IT and logistical management of EviMed.
Módulo 5: Paraproteínas & Enfermedad Renal.
Talk: Principios y novedades de la terapia anti-neoplásica en la GMSR
https://redemc.net/campus/wp-content/uploads/2021/10/Programa-OncoNefro-ES_Campus-1.pdf
Other
|
Online Course "Actualización en Onconefrología/ Update in Onconephology"
EviMed Research Group LLC, United States
|
2021/11/11 - 2021/11/13 | Invited Speaker at the Portuguese Society f Hematology Annual Meeting - Binding Site Symposium.: "Tecnologias inovadoras no
diagnóstico e seguimento de precisão do Mieloma Múltiplo /Novel technologies to diagnose and monitor Multiple Myeloma"
Meeting
|
Reunião Anual SPH 2021
Sociedade Portuguesa de Hematologia, Portugal
|
2021/11/01 - 2021/11/13 | Invited Speaker at the Portuguese Society of Hematology Annual Meeting - Conference on the Educational Program: "Maintenance
treatment for Multiple Myeloma".
Meeting
|
Portuguese Society of Hematology Annual Meeting 2021
Sociedade Portuguesa de Hematologia, Portugal
|
2018/07/18 - 2018/07/21 | Invited chairwoman at the ARVO-Champalimaud Foundation Ocular Oncogenesis & Oncology, Lisbon, Portugal
Conference
|
Ocular Oncogenesis & Oncology
Arvo Foundation for Eye Research, United States
Fundação Champalimaud, Portugal |
2016/10/28 - 2016/10/29 | Invited speaker in ASKLEPIOS Course, Lisbon, Portugal
Symposium
|
SYMPOSIUM ON IMAGING HALLMARKS OF CANCER – ESOR
Fundação Champalimaud, Portugal
European School of Radiology, Austria |
2016/09/22 - 2016/09/23 | Invited speacker in "Hematology Masterclass", Budapest, Hungary
Seminar
|
Hematology Medical Education Program
Janssen-Cilag Kft, Hungary
|
2016/02/08 - 2016/02/19 | Invited speaker in a Hematology Debate Meeting, Vienna, Austria
Meeting
|
Hematology Medical Education Program
Janssen-Cilag Pharma GmbH, Austria
|
2016 - 2016 | Invited speaker with lecture presentation: "New approaches from LLC- ibrutinib", Lisbon, Portugal
Conference
|
7ª Reunião Anual da Associação Portuguesa de Farmácias Hospitalares, 2016
Associação Portuguesa de Farmácias Hospitalares, Portugal
|
2014 - 2014 | Invited speaker with the titel "New therapies in Hemato-oncology and Immunotherapy and intra cellular signaling inhibition",
Lisbon, Portugal
Symposium
|
2014 Annual Meeting of the Portuguese Society of Human Genetics
Sociedade Portuguesa de Genética Humana, Portugal
|
Jury of academic degree
Topic Role |
Candidate name (Type of degree) Institution / Organization |
|
---|---|---|
2023/11/22 | Understanding the Role of Flower Code in Tumorigenesis
Thesis Member
|
Dénise dos Reis da Rosa de Azevedo Camacho (PhD)
Universidade Nova de Lisboa Instituto de Tecnologia Química e Biológica António Xavier, Portugal
|
Association member
Society Organization name | Role | |
---|---|---|
2016 - Current | International Myeloma Foundation | Membro activo |
2014 - Current | International Multiple Myeloma Working Group | Membro activo |
2009 - Current | European Hematology Association | Membro activo |
2000 - Current | Portuguese Society of Hematology | Membro activo |
1994 - 1994 | Students Association of the Faculty of Medicine of University of Lisbon |
Committee member
Activity description Role |
Institution / Organization | |
---|---|---|
2023/05/01 - Current | Board Member of the EuroFlow Consortium
Member
|
EuroFlow, Netherlands |
2020/12/22 - 2020/12/22 | Member of the jury for a doctoral thesis project in the Doctoral Program in Health Sciences at the University of Coimbra
Member
|
Universidade de Coimbra, Portugal |
1994 - 1995 | Elected member of the Senate of the University of Lisbon
Member
|
Conference scientific committee
Conference name | Conference host | |
---|---|---|
2024/03/01 - 2024/06/12 | European Haematology Association Annual Meeting (EHA2024 Hybrid Congress - Myeloma and other Monoclonal gammopathies) | Madrid, Spain |
2022/03/03 - 2022/03/14 | European Haematology Association Annual Meeting (EHA2022 Hybrid Congress) | Vienna |
Course / Discipline taught
Academic session | Degree Subject (Type) | Institution / Organization | |
---|---|---|---|
2023/04/11 - Current | Cancer immunotherapy - a global overview and clinical relevance | Doctoral Programme in Health Sciences - 14th edition (Doutoramento) | Universidade de Coimbra Faculdade de Medicina, Portugal |
2023/02/23 - 2023/02/25 | Immunology as a basis in the fight against multiple myeloma. | Perspectives in Hematology (Outros) | DNA Prime - Scientific Education, Portugal |
2016 - 2021/04 | Invited Professor of the Doctoral Program in Health Sciences - Oncobiology and Cancer Course | Curso de Oncobiologia e Cancro (Doutoramento) | Universidade de Coimbra Faculdade de Medicina, Portugal |
2010 - 2020 | Professor of Immunology | Medicina | Universidade Nova de Lisboa Faculdade de Ciências Médicas, Portugal |
2016/02/08 - 2016/02/19 | Hematology Debate Meeting, Hematology Medical Education Program | Hematology Medical Education (Postgraduate Certificate) | Janssen-Cilag Pharma GmbH, Austria |
Evaluation committee
Activity description Role |
Institution / Organization | Funding entity | |
---|---|---|---|
2021/03/01 - Current | External Reviewer, PhD Scholarship call, FCT, PT
Evaluator
|
Fundação para a Ciência e a Tecnologia, Portugal | Fundação para a Ciência e a Tecnologia |
2015 - Current | Member of the Examination Jury for a position of specialist in clinical hematology at Centro Hospitalar do Algarve
Evaluator
|
Centro Hospitalar do Algarve EPE, Portugal |
Interview (tv / radio show)
Program | Topic | |
---|---|---|
2023/04/03 - Current | Médico da Casa /House Physician | Multiple Myeloma |
2023/02/04 - Current | CNN Sábado | World Cancer Day is celebration (February 4th). The evolution in cancer therapies that have allowed a higher survival rate and a better quality of life for those diagnosed. |
2019/03/07 - Current | Guest speaker in the tv programme "Edição da Manhã" (SIC) | Multiple Myeloma |
2014/10/22 - Current | Guest speaker in the tv programme "Bom dia Portugal" (RTP) | Multiple Myeloma |
Journal scientific committee
Journal title (ISSN) | Publisher | |
---|---|---|
2021/10/13 - Current | Cancers (2072-6694) | MDPI |
2017/01/01 - Current | Cancers (2072-6694) | IMDP |
2017/01/01 - Current | International Journal of Molecular Sciences (1422-0067) | IMDP |
2017/01/01 - Current | Clinical Case Reports (2050-0904) | John Wiley & Sons Ltd |
2017/01/01 - Current | OncoTargets and Therapy (1178-6930) | Dove Medical Press Ltd |
Mentoring / Tutoring
Topic | Student name | |
---|---|---|
2019/08/19 - 2020/01/22 | Short term internship | Catarina Ventura |
2019/07/08 - 2019/08/31 | Summer Internship | Jácome Toste |
Distinctions
Award
2023 | Women in Science
Ciência Viva, Portugal
|
2022 | Prize José Eduardo Guimarães - Best work in Hematology |
2020 | Award Innovate Competition; iMed Conference 13,0
Universidade Nova de Lisboa, Portugal
|
2019 | Giled Génese
Gilead Sciences Lda, Portugal
|
2004 | Young Hematologist Award, Portuguese Society of Hematology
Sociedade Portuguesa de Hematologia, Portugal
|
Title
2018 | Consultant in Hematology
ACSS- Administração Central do Sistema de Saude, Portugal
|
Other distinction
2011 | Best Experimental Work
Sociedade Portuguesa de Hematologia, Portugal
|
2009 | 2º Best Experimental Work - Poster
Sociedade Portuguesa de Hematologia, Portugal
|
2003 | 1º Best Experimental Work - Poster
Sociedade Portuguesa de Hematologia, Portugal
|
2003 | Travel Award
American Association of nephrology, United States
|